Virus-Like Particles As an Instrument of Vaccine Production

Overview

Journal Mol Biol

Specialties Biochemistry
Biology

Date 2020 Mar 28

PMID 32214478

Citations 42

Authors

B V Syomin

Y V Ilyin

Affiliations

Soon will be listed here.

Abstract

The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target antigens on their surface have led to the development of universal platforms which make it possible for virtually any known antigen to be exposed on the particle surface in a highly concentrated form. As a result, the focus of attention has shifted from the approaches to VLP production to the development of a precise interface between the organism's immune system and the peptides inducing a strong immune response to pathogens or the organism's own pathological cells. Immunome-specified methods for vaccine design and the prospects of immunoprophylaxis are discussed. Certain examples of vaccines against viral diseases and cancers are considered.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

When synthetic biology meets medicine.

Feng Y, Su C, Mao G, Sun B, Cai Y, Dai J Life Med. 2025; 3(1):lnae010.

PMID: 39872399 PMC: 11749639. DOI: 10.1093/lifemedi/lnae010.

Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.

Bai Z, Wan D, Lan T, Hong W, Dong H, Wei Y ACS Nano. 2024; 18(36):24650-24681.

PMID: 39185745 PMC: 11394369. DOI: 10.1021/acsnano.3c10797.

Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.

Berreiros-Hortala H, Vilchez-Pinto G, Diaz-Perales A, Garrido-Arandia M, Tome-Amat J Int J Mol Sci. 2024; 25(13).

PMID: 39000536 PMC: 11242184. DOI: 10.3390/ijms25137429.

Pulmonary inhalation for disease treatment: Basic research and clinical translations.

Wang B, Wang L, Yang Q, Zhang Y, Qinglai T, Yang X Mater Today Bio. 2024; 25:100966.

PMID: 38318475 PMC: 10840005. DOI: 10.1016/j.mtbio.2024.100966.

References

Zakeri B, Fierer J, Celik E, Chittock E, Schwarz-Linek U, Moy V . Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A. 2012; 109(12):E690-7. PMC: 3311370. DOI: 10.1073/pnas.1115485109. View

Shao J, Wong C, Lin T, Lee S, Cong G, Sin F . Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol. 2010; 18(1):143-9. PMC: 3019777. DOI: 10.1128/CVI.00236-10. View

Wesolowska A, Kozak Ljunggren M, Jedlina L, Basalaj K, Legocki A, Wedrychowicz H . A Preliminary Study of a Lettuce-Based Edible Vaccine Expressing the Cysteine Proteinase of for Fasciolosis Control in Livestock. Front Immunol. 2018; 9:2592. PMC: 6244665. DOI: 10.3389/fimmu.2018.02592. View

Balke I, Zeltins A . Use of plant viruses and virus-like particles for the creation of novel vaccines. Adv Drug Deliv Rev. 2018; 145:119-129. DOI: 10.1016/j.addr.2018.08.007. View

Smith M, Lindbo J, Dillard-Telm S, Brosio P, Lasnik A, McCormick A . Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 2006; 348(2):475-88. DOI: 10.1016/j.virol.2005.12.039. View

Moraes A, Jorge S, Astray R, Suazo C, Calderon Riquelme C, Augusto E . Drosophila melanogaster S2 cells for expression of heterologous genes: From gene cloning to bioprocess development. Biotechnol Adv. 2011; 30(3):613-28. DOI: 10.1016/j.biotechadv.2011.10.009. View

Mohsen M, Gomes A, Cabral-Miranda G, Krueger C, Leoratti F, Stein J . Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. 2017; 251:92-100. DOI: 10.1016/j.jconrel.2017.02.031. View

Zhang Y . Template-based modeling and free modeling by I-TASSER in CASP7. Proteins. 2007; 69 Suppl 8:108-17. DOI: 10.1002/prot.21702. View

Mastico R, Talbot S, Stockley P . Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J Gen Virol. 1993; 74 ( Pt 4):541-8. DOI: 10.1099/0022-1317-74-4-541. View

10.

Syomin B, FEDOROVA L, Surkov S, Ilyin Y . The endogenous Drosophila melanogaster retrovirus gypsy can propagate in Drosophila hydei cells. Mol Gen Genet. 2001; 264(5):588-94. DOI: 10.1007/s004380000344. View

11.

Ho S, Yang Y . Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells. Biotechnol Lett. 2014; 36(8):1569-79. DOI: 10.1007/s10529-014-1523-4. View

12.

Pan Q, He K, Huang K . Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine. 2008; 26(17):2119-26. DOI: 10.1016/j.vaccine.2008.02.037. View

13.

Bolton D, Song K, Tomaras G, Rao S, Roederer M . Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. Vaccine. 2017; 35(4):639-646. PMC: 5241230. DOI: 10.1016/j.vaccine.2016.12.008. View

14.

Li P, Qiao X, Zheng Q, Hou J . Immunogenicity and immunoprotection of porcine circovirus type 2 (PCV2) Cap protein displayed by Lactococcus lactis. Vaccine. 2015; 34(5):696-702. DOI: 10.1016/j.vaccine.2015.09.007. View

15.

Smith M, Hawes A, Bundy B . Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr Opin Biotechnol. 2013; 24(4):620-6. DOI: 10.1016/j.copbio.2013.01.011. View

16.

Bates P, Kelley L, MacCallum R, STERNBERG M . Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins. 2002; Suppl 5:39-46. DOI: 10.1002/prot.1168. View

17.

Lambert C, Leonard N, De Bolle X, Depiereux E . ESyPred3D: Prediction of proteins 3D structures. Bioinformatics. 2002; 18(9):1250-6. DOI: 10.1093/bioinformatics/18.9.1250. View

18.

OBrien G, Bryant C, Voogd C, Greenberg H, Gardner R, Bellamy A . Rotavirus VP6 expressed by PVX vectors in Nicotiana benthamiana coats PVX rods and also assembles into viruslike particles. Virology. 2000; 270(2):444-53. DOI: 10.1006/viro.2000.0314. View

19.

Jager S, Cimermancic P, Gulbahce N, Johnson J, McGovern K, Clarke S . Global landscape of HIV-human protein complexes. Nature. 2011; 481(7381):365-70. PMC: 3310911. DOI: 10.1038/nature10719. View

20.

Musiychuk K, Stephenson N, Bi H, Farrance C, Orozovic G, Brodelius M . A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses. 2009; 1(1):19-25. PMC: 4634661. DOI: 10.1111/j.1750-2659.2006.00005.x. View